[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Staar Surgical Company (STAA)

Staar Surgical Company (STAA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

STAAR Surgical Reports Wednesday With Sales That More Than Doubled

Staar Surgical Company (STAA) reports second-quarter fiscal 2026 earnings tomorrow, August 12, after market close, with analysts expecting a return to profitability after a volatile year of earnings surprises. The central question: can the ophthalmic medical device maker sustain the momentum from its blowout first-quarter beat, or will the pattern of extreme volatility continue? With the stock trading near its 200-day moving average and analyst sentiment deteriorating, this report will test whether STAA's recent operational improvements can translate into consistent earnings performance.

Staar Surgical Company develops, manufactures, and markets implantable lenses for the eye, with its flagship EVO Implantable Collamer Lens (ICL)...

Fundamentals

See More
  • Market Capitalization, $K 1,241,713
  • Shares Outstanding, K 49,788
  • Annual Sales, $ 239,440 K
  • Annual Income, $ -80,450 K
  • EBIT $ -26 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.26
  • Price/Sales 5.22
  • Price/Cash Flow N/A
  • Price/Book 3.55

Options Overview Details

View History
  • Implied Volatility 66.04% (-1.31%)
  • Historical Volatility 56.10%
  • IV Percentile 62%
  • IV Rank 49.47%
  • IV High 116.65% on 10/06/25
  • IV Low 16.51% on 08/25/25
  • Expected Move (DTE 8) 2.41 (9.47%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 1,129
  • Volume Avg (30-Day) 275
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 12,036
  • Open Int (30-Day) 10,896
  • Expected Range 23.00 to 27.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 3
  • High Estimate $0.03
  • Low Estimate $-0.09
  • Prior Year $0.30
  • Growth Rate Est. (year over year) -110.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.19 +19.89%
on 07/28/26
29.91 -15.06%
on 07/16/26
-2.35 (-8.47%)
since 07/10/26
3-Month
21.19 +19.89%
on 07/28/26
35.87 -29.16%
on 05/14/26
-2.77 (-9.83%)
since 05/12/26
52-Week
15.59 +63.04%
on 02/17/26
35.87 -29.16%
on 05/14/26
-1.98 (-7.23%)
since 08/12/25

Most Recent Stories

More News
STAAR Surgical (NASDAQ:STAA) Delivers Strong Q2 CY2026 Numbers But Stock Drops

STAAR Surgical (NASDAQ:STAA) Delivers Strong Q2 CY2026 Numbers But Stock Drops

STAA : 25.41 (+1.88%)
Staar Surgical: Q2 Earnings Snapshot

Staar Surgical: Q2 Earnings Snapshot

STAA : 25.41 (+1.88%)
STAAR Surgical Reports Second Quarter 2026 Results

Net Sales of $93.5 million, up 111% Y/Y Net Income of $8.1 million, with GAAP EPS of $0.16 Adjusted EBITDA ...

STAA : 25.41 (+1.88%)
STAAR Surgical Reports Wednesday With Sales That More Than Doubled

Barchart Research What to Expect from STAA Earnings STAA Generated August 11, 2026 Current Price $24.94 EPS Estimate $$0.05 Consensus Rating Hold Average Move 6.75% STAAR Surgical Reports Wednesday With...

STAA : 25.41 (+1.88%)
What To Expect From STAAR Surgical’s (STAA) Q2 Earnings

What To Expect From STAAR Surgical’s (STAA) Q2 Earnings

STAA : 25.41 (+1.88%)
1 Stock Under $50 on Our Buy List and 2 We Ignore

1 Stock Under $50 on Our Buy List and 2 We Ignore

HUBG : 40.21 (+5.82%)
SMCI : 37.61 (+19.02%)
STAA : 25.41 (+1.88%)
STAAR Surgical: The ICL Installed Base Keeps Growing But Revenue Per Lens Doesn't

Barchart Research What to Expect from STAA Earnings STAA Generated August 4, 2026 Current Price $24.12 EPS Estimate $$0.06 Consensus Rating Hold Average Move 6.75% STAAR Surgical: The ICL Installed Base...

STAA : 25.41 (+1.88%)
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

Deborah Andrews appointed Executive Vice President and Chief Financial Officer

STAA : 25.41 (+1.88%)
STAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial...

STAA : 25.41 (+1.88%)
1 High-Flying Stock with Impressive Fundamentals and 2 We Question

1 High-Flying Stock with Impressive Fundamentals and 2 We Question

UAA : 5.26 (-1.50%)
STAA : 25.41 (+1.88%)
HEI : 373.10 (+1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.

See More

Key Turning Points

3rd Resistance Point 27.42
2nd Resistance Point 26.72
1st Resistance Point 26.07
Last Price 25.41
1st Support Level 24.72
2nd Support Level 24.02
3rd Support Level 23.37

See More

52-Week High 35.87
Fibonacci 61.8% 28.12
Fibonacci 50% 25.73
Last Price 25.41
Fibonacci 38.2% 23.33
52-Week Low 15.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.